InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
2
T+90 hit rate
100%
T+90 mean return
+177.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Morabito Christopher, Directeur Médical. Insider active across 2 companies, notably Fulcrum Therapeutics, Inc.. Aggregated, 7 reports have been published. Split: 2 buys · 2 sells. Total volume traded: €120k. History available since 28 June 2021. The latest transaction was disclosed on 1 April 2024 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations7 total
10,000 shares@ US$3.8720.7% of flowCommon StockSEC:0001104659-24-043092:0
800 shares@ US$3.871.6% of flowCommon StockSEC:0001104659-24-008327:0
800 shares@ US$11.0154.7% of flowCommon StockSEC:0001104659-24-008327:1
9,200 shares@ US$3.8718.8% of flowCommon StockSEC:0001104659-24-008327:2
9,200 shares@ US$11.14754.2% of flowCommon StockSEC:0001104659-24-008327:3
1,100 shares@ US$9.1650.0% of flowCommon StockSEC:0000899243-21-026557
Ideal exit: 25 Mar 2022 (T+270)
1,100 shares@ US$9.160.0019% mcap50.0% of flowCommon StockSEC:0000899243-21-026557:0
Ideal exit: 25 Mar 2022 (T+270)
7 of 7 declarations
About Morabito Christopher
Christopher Morabito is the Chief Medical Officer at Fulcrum Therapeutics, Inc. In this role, he is responsible for leading the company's clinical initiatives and medical research. With a strong background in the biopharmaceutical sector, Christopher plays a key role in developing innovative therapies. His expertise is essential to ensure regulatory compliance and the effectiveness of clinical trials at Fulcrum.
